0001104659-21-037330.txt : 20210316
0001104659-21-037330.hdr.sgml : 20210316
20210316211235
ACCESSION NUMBER: 0001104659-21-037330
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210312
FILED AS OF DATE: 20210316
DATE AS OF CHANGE: 20210316
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wicki Andreas
CENTRAL INDEX KEY: 0001511472
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 21748158
MAIL ADDRESS:
STREET 1: C/O HBM BIOVENTURES (CAYMAN) LTD.
STREET 2: CENTENNIAL TOWERS,STE.305,2454 W.BAY RD.
CITY: GRAND CAYMAN
STATE: E9
ZIP: E9
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira BioSciences, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 510619477
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: 973-254-3560
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20101029
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
4
1
tm219971-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-03-12
0
0001396814
Pacira BioSciences, Inc.
PCRX
0001511472
Wicki Andreas
GOVERNORS SQUARE, SUITE 4-212-2
23 LIME TREE BAY AVE, WEST BAY
GRAND CAYMAN
E9
00000
CAYMAN ISLANDS
1
0
0
0
Common Stock
2021-03-12
4
S
0
58754
73.10
D
461925
I
See Footnote
Common Stock
2021-03-15
4
S
0
10601
73.68
D
451324
I
See Footnote
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.20 to $73.62, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (1) of this Form 4.
These shares are held by HBM Healthcare Investments (Cayman) Ltd. ("HBM"), of which Mr. Wicki is a member of the board of directors. The board of directors of HBM acts by majority vote, and Mr. Wicki does not have sole voting or investment power with respect to the shares. Mr. Wicki disclaims beneficial ownership of such shares for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purposes of Section 16 of the Exchange Act, or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.405 to $74.54, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote three (3) of this Form 4.
/S/ MEHDI KHODADAD, ATTORNEY-IN-FACT
2021-03-16